Safety and Pharmacokinetics of Ifetroban in Hepatorenal Syndrome Patients
Conditions
Hepatorenal Syndrome
What is the purpose of this trial?
Cumberland Pharmaceuticals Inc. (CPI) is developing ifetroban for treatment of hepatorenal syndrome (HRS) and proposes to conduct a study in hospitalized adult patients with HRS to assess the safety and pharmacokinetics of escalating doses of ifetroban.
Participation Guidelines
- Age:
- 18 Years and older
- Gender:
- Both
Click here for detailed information about who can participate in this trial.
- Sponsor:
- Cumberland Pharmaceuticals
- Dates:
- October 2011
- Last Updated:
- January 25, 2013
- Study HIC#:
- 1106008595
Clinicaltrials.gov ID: NCT01436500
For more information about this trial, contact:
Danielle Jacques
203-785-7031
danielle.lettieri@yale.edu
Investigator
Sukru Emre, MD
Principal Investigator
